ArrowMark Colorado Holdings LLC Sells 1,131,450 Shares of Certara, Inc. (NASDAQ:CERT)

ArrowMark Colorado Holdings LLC trimmed its position in shares of Certara, Inc. (NASDAQ:CERT) by 32.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,351,604 shares of the company’s stock after selling 1,131,450 shares during the quarter. ArrowMark Colorado Holdings LLC owned 1.46% of Certara worth $27,537,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Paloma Partners Management Co bought a new position in Certara during the third quarter valued at about $413,000. 272 Capital LP bought a new position in shares of Certara in the third quarter worth $177,000. Wasatch Advisors LP grew its holdings in Certara by 22.4% during the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after buying an additional 1,651,076 shares in the last quarter. Edgestream Partners L.P. bought a new stake in Certara during the 3rd quarter worth approximately $1,782,000. Finally, Glenmede Trust Co. NA boosted its stake in Certara by 78.6% during the third quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock valued at $14,123,000 after buying an additional 530,598 shares during the period. 73.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CERT shares. Robert W. Baird lowered their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $15.92.

Insiders Place Their Bets

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 33.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by company insiders.

Certara Stock Down 0.5 %

CERT opened at $11.21 on Monday. The company has a market capitalization of $1.80 billion, a PE ratio of -56.05, a price-to-earnings-growth ratio of 5.67 and a beta of 1.51. The firm has a 50-day simple moving average of $10.81 and a two-hundred day simple moving average of $12.98. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87.

Certara (NASDAQ:CERT) last released its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue was up 10.7% on a year-over-year basis. During the same quarter last year, the business earned $0.06 EPS. Analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.